Processa Pharmaceuticals, Inc.

What they do

Processa is a clinical-stage biotech with no product revenue; it develops drug candidates and funds operations through equity and preferred stock financings. Its lead asset, VT-7208, came with the July 28, 2026 acquisition of Vidya Therapeutics and is a Bruton's tyrosine kinase inhibitor being developed for immune-mediated diseases, initially food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis. The company also continues development of legacy assets PCS499, PCS12852 and PCS11T. The PCS6422 program, licensed from Elion Oncology, was terminated in a July 2026 settlement and returned to Elion, and the related Phase 2 trial in advanced or metastatic breast cancer is being closed.

Revenue drivers

• Product revenue — No product revenue is reported in the recent XBRL data; annual revenue was $0.00 in 2021 and 2022, and the most recent quarterly revenue figures shown are $0.00 for 2022-03-31 and 2023-03-31. The only positive revenue in the dataset is from 2014-2016 ($107,239 in 2014, $113,425 in 2015, $5,000 in 2016).
• VT-7208 (acquired with Vidya) — Pipeline asset, not a revenue source today; it is a BTK inhibitor for immune-mediated diseases with initial focus on food allergy, CSU and RMS. Management expects to fund it through Phase 2 proof-of-concept data using proceeds from the $200 million private placement.
• Legacy assets PCS499, PCS12852 and PCS11T — Development-stage candidates that generate no revenue; the company says it is continuing their development while evaluating strategic options. Under the Elion settlement, Elion receives a non-voting equity interest equal to 7.5% of the fully diluted pre-money capitalization of any newly formed entity holding PCS499, PCS12852 or PCS11T if formed within 365 days.
• Equity and preferred stock financing — The company funds itself through securities sales rather than product sales. Recent examples include a February 2026 private placement of 86,956 shares for $200,000, roughly $207,000 of purchases by directors, officers and employees, about $153,000 in net proceeds from 50,330 ATM shares in April 2026, and the $200 million gross / $183.3 million net preferred placement tied to the Vidya acquisition.

Recent performance

The company reported no revenue in the recent annual and quarterly periods shown, consistent with its clinical-stage status. Annual net income was negative in 2021 through 2024 (-$11.4M, -$27.4M, -$11.1M and -$11.8M) but positive $13.6M in 2025, alongside diluted EPS of -$10.36 for 2025. Operating cash flow has been negative every year shown, from -$8.7M in 2021 to -$11.4M in 2025. At June 30, 2026, total assets were $2.1M, total liabilities $2.4M, cash and equivalents $196,325, and shareholders' equity was negative $317,341.

Strategy

The stated direction is to advance the newly acquired VT-7208 through Phase 2 proof-of-concept studies in food allergy, CSU and RMS, funded by the $200 million gross private placement of non-voting convertible preferred stock. Management says the $183.3 million in net proceeds is intended to fund operations into the second half of 2029 and through key clinical milestones. The company is also continuing its legacy assets PCS499, PCS12852 and PCS11T while evaluating strategic opportunities for them, and has settled the Elion litigation, terminating the PCS6422 license and closing that Phase 2 trial. Other 2026 financings included small private placements and ATM sales.

Risks

• Going concern and limited cash — The company has a history of losses and, at June 30, 2026, had only $196,325 of cash, $2.4M of liabilities against $2.1M of assets, and negative shareholders' equity of $317,341.
• Dependence on a newly acquired asset — The pipeline now hinges on VT-7208, acquired with Vidya in July 2026, which has not generated revenue and still requires Phase 2 proof-of-concept data in food allergy, CSU and RMS.
• Financing and dilution risk — Operations are funded by equity issuance, including the $200 million non-voting convertible preferred placement, the February 2026 private placement of 86,956 shares for $200,000, and ATM sales of 50,330 shares for about $153,000, all of which dilute existing holders.
• Clinical and regulatory risk — The company's forward-looking statements cite risks including ability to secure required FDA or other governmental approvals, the breadth of indications sought, and competition from alternative products and technologies.

Outlook

Management says the $183.3 million in net proceeds from the Vidya-related preferred placement should fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, CSU and RMS. The 10-Q also flags risks to remaining listed on the Nasdaq Capital Market and to continuing as a going concern. The company states it will keep developing its legacy assets while evaluating strategic opportunities to maximize their value.